KR20110047824A - Cosmetic composition containing citron extract - Google Patents
Cosmetic composition containing citron extract Download PDFInfo
- Publication number
- KR20110047824A KR20110047824A KR1020090104601A KR20090104601A KR20110047824A KR 20110047824 A KR20110047824 A KR 20110047824A KR 1020090104601 A KR1020090104601 A KR 1020090104601A KR 20090104601 A KR20090104601 A KR 20090104601A KR 20110047824 A KR20110047824 A KR 20110047824A
- Authority
- KR
- South Korea
- Prior art keywords
- citron
- extract
- cosmetic composition
- composition containing
- seed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 240000004307 Citrus medica Species 0.000 title claims abstract description 59
- 239000000284 extract Substances 0.000 title claims abstract description 45
- 239000002537 cosmetic Substances 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000002087 whitening effect Effects 0.000 claims abstract description 7
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 5
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- -1 blocker Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003205 fragrance Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims description 2
- 239000012965 benzophenone Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000004088 foaming agent Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 229930195143 oxyphenol Natural products 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 229930003935 flavonoid Natural products 0.000 abstract description 10
- 235000017173 flavonoids Nutrition 0.000 abstract description 10
- 150000002215 flavonoids Chemical class 0.000 abstract description 9
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 235000020971 citrus fruits Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000002510 keratinocyte Anatomy 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000207199 Citrus Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 4
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 4
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 4
- 101710200814 Melanotropin alpha Proteins 0.000 description 4
- ZIKZPLSIAVHITA-UHFFFAOYSA-N Nomilinic acid Natural products CC(=O)OC(CC(O)=O)C1(C)C(C(C)(C)O)CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 ZIKZPLSIAVHITA-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 4
- 229940025878 hesperidin Drugs 0.000 description 4
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 4
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 4
- KPDOJFFZKAUIOE-WNGDLQANSA-N nomilin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@H]2C(C)(C)OC(=O)C[C@@H]([C@]42C)OC(=O)C)C=COC=1 KPDOJFFZKAUIOE-WNGDLQANSA-N 0.000 description 4
- KPDOJFFZKAUIOE-HPFWCIFASA-N nomilin Natural products O=C(O[C@H]1[C@@]2(C)[C@@H](C(C)(C)OC(=O)C1)CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@H](c3cocc3)OC(=O)[C@@H]3O[C@@]123)C KPDOJFFZKAUIOE-HPFWCIFASA-N 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010051246 Photodermatosis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008845 photoaging Effects 0.000 description 3
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037330 wrinkle prevention Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명의 실시예들은 유자 추출물을 포함하는 화장료 조성물에 관한 것이다.Embodiments of the present invention relates to a cosmetic composition comprising a citron extract.
본 발명의 실시예들은 유자 추출물을 포함하는 화장료 조성물의 제조방법에 관한 것이다.Embodiments of the present invention are directed to a method of preparing a cosmetic composition comprising the citron extract.
본 발명의 실시예들에 따른 유자 추출물을 포함하는 화장료 조성물은 미백, 노화방지, 항산화 및 항염증 효과를 가진다. Cosmetic composition comprising citron extract according to the embodiments of the present invention has a whitening, anti-aging, antioxidant and anti-inflammatory effect.
유자 추출물, 플라보노이드 Citron Extract, Flavonoids
Description
본 발명의 실시예들은 유자 추출물을 포함하는 화장료 조성물에 관한 것이다.Embodiments of the present invention relates to a cosmetic composition comprising a citron extract.
유자는 한국, 중국, 일본을 비롯해 동북아시아에서 생산되는 감귤류의 일종이다. 한국산이 가장 향이 진하고 껍질이 두껍다. 국내 주요 산지로는 전라남도 고흥·완도·장흥·진도, 제주도 등이다.Citron is a kind of citrus produced in Northeast Asia including Korea, China and Japan. Korea has the strongest fragrance and thickest skin. Korea's major producing regions are Goheung, Wando, Jangheung, Jindo, and Jeju Island, Jeollanam-do.
유자의 주요 성분으로 비타민C가 레몬보다 3배 많이 들어 있어 감기와 피부미용에 좋고, 노화와 피로를 방지하는 유기산이 많이 들어있다. 그밖에 비타민B와 당질, 단백질 등이 다른 감귤류 과일보다 많고 모세혈관을 보호하는 플라보노이드류 등이 들어 있어 뇌혈관 장애와 풍을 막아준다. 또한, 배농 및 배설작용을 해서 몸 안에 쌓여 있는 노폐물을 밖으로 내보낸다.As the main ingredient of citron, vitamin C contains three times more than lemon, which is good for colds and skin care, and contains many organic acids that prevent aging and fatigue. In addition, vitamin B, sugars, and protein are more than other citrus fruits and contain flavonoids that protect capillaries, thereby preventing cerebrovascular disorders and wind. It also drains and excretes the waste that builds up in the body.
감귤류에 존재하는 플라보노이드 및 리모노이드 화합물은 생리활성 효과가 매우 높다. 유자씨 중의 나린게닌(naringenin), 헤스페리딘(hesperidin) 및 노빌레 틴(bobiletin) 등과 같은 플라보노이드는 대장암 치료효과가 있다고 보고되었으며, 나린게닌(naringenin)과 헤스페리딘(hesperedin)이 마우스에서 유방 지방종양의 발현을 억제하였고 이들 종양의 림프절전이나 폐 전이를 저해하였다는 보고도 있다. 그 외에도 감귤류 플라보노이드가 종양생성 촉진제의 활성을 억제하였다는 보고와 암조직 내에 들어오는 치료약을 조직 밖으로 펌프질하여 내보내는 암세포의 항암제 내성 유전자의 활성도 억제한다는 보고도 있다. Flavonoid and limonoid compounds present in citrus fruits have a very high bioactive effect. Flavonoids such as naringenin, hesperidin, and nobiletin in citron seeds have been reported to be effective in treating colorectal cancer. It has also been reported to inhibit expression and inhibit lymph node or lung metastasis of these tumors. In addition, it has been reported that citrus flavonoids inhibit the activity of tumor growth promoters, and also inhibit the activity of anticancer drug resistance genes of cancer cells that pump out therapeutic drugs entering cancer tissues.
플라보노이드 화합물이 혈중 콜레스테롤의 함량을 저하시킨다는 연구결과와 감귤 플라보노이드가 비타민과 같은 작용으로 항바이러스, 항세균, 항곰팡이 작용을 한다는 연구결과도 있다. 감귤류 리모노이드 화합물 특히 리모닌(limonin)과 노밀린(nomilin)이 위암, 폐암, 피부암 등을 억제한다는 보고가 있고 최근에는 유방암을 효과적으로 억제한다는 연구결과도 보고되고 있다.There are also studies showing that flavonoid compounds lower blood cholesterol levels and that citrus flavonoids have antiviral, antibacterial and antifungal effects by acting like vitamins. Citrus limonoid compounds, in particular, limonin (limonin) and nomilin (nomilin) has been reported to suppress stomach cancer, lung cancer, skin cancer, etc. Recently, studies have been reported to effectively inhibit breast cancer.
국내 기능성 화장품법에 의하면 기능성 화장품은 항노화 주름방지, 미백, 그리고 자외선에 대한 피부보호 등에 대한 효능이 있는 것으로 정의되어 있다. 피부노화(skin aging)는 자외선에 장기간 노출된 피부에서 관찰되는 광노화(photoaging)와 비노출부에서 관찰되는 내인성 노화(intrinsic aging, chronological aging)로 나눌 수 있으며 피부노화의 원인의 70% 이상은 광노화에 있다. 자외선은 태양으로부터 오는 여러 에너지 중에서 피부의 노화에 가장 많은 영향을 미치는 것으로 알려져 있다. 이러한 자외선의 효과는 무모생쥐에 자외선을 조사하면 주름살이 형성되는 것으로 알 수 있으며 또한, 배양된 섬유아세포(fibroblasts)에 자외선을 조사하면 피부의 기질단백질인 교원질(procollagen)의 발현이 감소하고 MMP-1의 발현 이 증가하는 것으로 중요성을 알 수 있다.According to the domestic functional cosmetics law, functional cosmetics are defined as having an effect on anti-aging wrinkle prevention, whitening, and skin protection against ultraviolet rays. Skin aging can be divided into photoaging observed in skin exposed to ultraviolet rays for a long time and intrinsic aging (chronological aging) observed in non-exposed areas, and more than 70% of the causes of skin aging are caused by photoaging. have. Ultraviolet rays are known to have the greatest effect on skin aging, among other energy sources from the sun. The effect of ultraviolet rays is that wrinkles are formed when UV rays are irradiated to hairless mice. Also, when UV rays are irradiated to cultured fibroblasts, expression of collagen (procollagen), which is a skin protein, decreases and MMP- The importance of 1 expression is increased.
모든 기능성화장품에는 기본적으로 자외선에 대한 피부손상을 방지할 수 있는 기능성 생리활성 소재가 사용되고 있으며 최근 세계적인 기술개발 동향은 천연물로부터 얻어진 항산화소재의 개발이 활발한 추세이다. 따라서 유자의 알려진 성분인 헤스페리딘, 카로티노이드 및 비타민 C 성분을 이용한 자외선 제품의 개발이 가능하며, 특히 헤스페리딘은 신규 플라보노이드로서 잠재적 가능성이 매우 크다고 할 수 있다.Basically, all functional cosmetics use functional physiologically active materials that can prevent skin damage to ultraviolet rays. Recently, the global trend of technological development is actively developing antioxidant materials obtained from natural products. Therefore, it is possible to develop ultraviolet light products using known components of citron hesperidin, carotenoids and vitamin C. In particular, hesperidin has a great potential as a novel flavonoid.
감귤류에 존재하는 플라보노이드 및 리모노이드 화합물이 생리활성 효과가 매우 높다는 것은 위에서 예시한 것 이외에도 수없이 많은 연구결과들이 발표되고 있다. 특히 씨앗에는 이들 물질이 과피나 조직보다 훨씬 많이 함유되어 있는 것으로 알려져 있다. 그러나 우리나라에서 유자의 이용은 주로 유자청 제조에 이용되고 있어 전체과일의 약 10~15%정도를 차지하는 씨앗은 연간 1,800톤 전량 폐기처분되고 있다.Numerous studies have been published in addition to those illustrated above that the flavonoid and limonoid compounds present in citrus fruits have a very high physiological activity. Seeds in particular are known to contain much more of these substances than rinds and tissues. However, in the country, the use of citron is mainly used for the production of citron, and the seeds which occupy about 10-15% of the whole fruit are disposed of all 1,800 tons per year.
따라서, 유자부산물인 유자씨 추출물을 이용한 새로운 기능성 화장품 소재의 개발은 산업 폐기물에서 신기능성 화장료로의 고부가가치 제품으로 전환 가능성이 크며, 이에 유자씨 추출물을 통한 새로운 기능성 화장품 소재를 개발하는 것이 매우 필요한 상황이다.Therefore, the development of a new functional cosmetic material using citron seed extract, which is a citron by-product, is likely to be converted into a high value-added product from industrial waste to a new functional cosmetic, and thus, it is very necessary to develop a new functional cosmetic material through citron seed extract. Situation.
본 발명의 실시예들은 유자 추출물을 포함하는 화장료 조성물을 제공하고자 한다.Embodiments of the present invention to provide a cosmetic composition comprising a citron extract.
상기 과제의 해결을 위해, 본 발명의 실시예들은 유자 추출물을 포함하는 화장료 조성물을 제공한다. In order to solve the above problems, embodiments of the present invention provides a cosmetic composition comprising a citron extract.
또한 본 발명의 실시예들은 유자로부터 상기 유자 추출물을 추출하는 방법을 제공한다. Embodiments of the present invention also provide a method of extracting the citron extract from the citron.
본 발명의 실시예들에 따른 화장료 조성물은 피부노화억제, 자외선에 의한 피부염증 완화를 통한 광노화 억제 및 미백 효과를 가진다. The cosmetic composition according to the embodiments of the present invention has a skin aging inhibitory effect, a photoaging inhibitory effect and a whitening effect through skin irritation relief by ultraviolet rays.
본 발명의 실시예들은 유자 추출물을 포함하는 화장료 조성물을 제공한다. Embodiments of the present invention provide a cosmetic composition comprising a citron extract.
본 발명의 다른 구체예에서 유자는 유자 과피 또는 유자 씨만을 사용할 수 있으며, 본 발명의 유자 추출물은 나리게닌(naringenin), 헤스페리딘(hesperidin) 및 노빌레틴(nobiletin) 등과 같은 플라보노이드를 포함할 수 있다. 또한 본 발명 의 유자 추출물은 리모닌(limonin)과 노밀린(nomilin)을 포함 할 수 있다. In another embodiment of the present invention, the citron may use only citron rind or citron seed, and the citron extract of the present invention may include flavonoids such as naringenin, hesperidin, nobiletin and the like. In addition, the citron extract of the present invention may include limonin (limonin) and nomilin (nomilin).
본 발명의 실시예들은 유자 추출물을 포함하는 화장료 조성물을 제공한다. Embodiments of the present invention provide a cosmetic composition comprising a citron extract.
하기 실시예를 통해서 알 수 있듯이, 본 발명의 일실시예에 따른 유자 추출물을 포함하는 화장료 조성물은 항노화, 항염증 및 미백 효과가 우수하다. 따라서 피부노화 방지나 미백용 기능성 화장품의 제조에 유용하게 사용될 수 있다. As can be seen through the following examples, the cosmetic composition comprising the citron extract according to an embodiment of the present invention is excellent in anti-aging, anti-inflammatory and whitening effect. Therefore, it can be usefully used in the manufacture of functional cosmetics for preventing skin aging or whitening.
본 발명의 한 구체예에서, 본 발명의 유자 추출물을 포함하는 화장료 조성물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비인온형 유화제, 충전제, 금속이온 봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 첨가제를 사용할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. In one embodiment of the invention, in addition to the cosmetic composition comprising the citron extract of the present invention, fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents ), Fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles Or additives commonly used in the field of dermatology, such as any other ingredients commonly used in external preparations for the skin. The ingredients may also be introduced in amounts generally used in the field of dermatology.
본 발명의 일실시예에 따르면 유자 추출물을 포함하는 화장료 조성물이 사용되는 화장품은 그 제형에 있어서 이에 한정되는 것은 아니지만 예를 들어 유연화장수, 영양화장수, 마사지크림, 영양크림, 팩, 젤, 에센스, 립스틱, 메이크업 베이스, 파운데이션, 로션, 연고, 겔, 크림, 클렌징, 세안제, 비누, 샴푸, 린스, 트리트먼트 및 미용액일 수 있다. 이러한 화장품은 수성 비타민, 유성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 등의 통상의 성분들을 포함할 수 있으며, 당업자에게 널리 공지된 기술에 따라 용이하게 제조될 수 있다. According to one embodiment of the present invention, the cosmetic composition containing the citron extract is used, but the cosmetic composition is not limited thereto. For example, supple cosmetics, nourishing cosmetics, massage creams, nourishing creams, packs, gels, essences, Lipstick, makeup base, foundation, lotion, ointment, gel, cream, cleansing, face wash, soap, shampoo, rinse, treatment and essence. Such cosmetics may include conventional ingredients such as aqueous vitamins, oily vitamins, polymer peptides, polymer polysaccharides, sphingolipids, and the like, and may be readily prepared according to techniques well known to those skilled in the art.
본 발명의 일실시예에 따르면 유자 추출물을 포함하는 화장료의 함량은 이에 한정되는 것은 아니지만 화장료 조성물 총 중량에 대하여 0.001 내지 30 중량 %, 0.001 내지 15 중량 %, 또는 0.001 내지 5 중량 % 일 수 있다. 바람직하게는 0.02 내지 0.2 중량 % 를 사용한다. According to one embodiment of the present invention, the content of the cosmetic including the citron extract may be 0.001 to 30% by weight, 0.001 to 15% by weight, or 0.001 to 5% by weight based on the total weight of the cosmetic composition. Preferably from 0.02 to 0.2% by weight is used.
본 발명의 실시예들은 유자 추출물의 제조방법을 제공한다.Embodiments of the present invention provide a method for preparing citron extract.
유자를 과피, 속씨, 씨앗껍질 별로 분류하여 분류된 부위별로 동결건조한다. 그 후 건조 분말상태로 저온에서 보관한다. 보관하는 온도는 -50℃ 내지 -5℃가 적당하며 바람직하게는 -30℃ 내지 -10℃가 좋다. Citron is classified by skin, genus seeds and seed shells and lyophilized by classified parts. Thereafter, stored at low temperature in a dry powder state. As for the temperature to store, -50 degreeC --5 degreeC is suitable, Preferably -30 degreeC --10 degreeC is good.
각 분말을 유기용매로 열수 추출한다. 이때 유기용매의 양은 분말 100중량부 대비 500중량부 내지 1500중량부를 사용하는 것이 좋다. 열수의 온도는 40℃ 내지 80℃, 바람직하게는 50℃ 내지 70℃가 좋다. Each powder is hydrothermally extracted with an organic solvent. At this time, the amount of the organic solvent is preferably used 500 parts by weight to 1500 parts by weight relative to 100 parts by weight of powder. The temperature of the hot water is 40 ° C to 80 ° C, preferably 50 ° C to 70 ° C.
유기용매는 당업계에서 통상적으로 사용되는 유기용매를 사용할 수 있으며, 예로는 이에 한정되지 않으나 페녹시에탄올, 프로피파라벤, 옥시페놀, 벤조페논 및 에탄올 등의 알코올류가 적당하며 바람직하게는 에탄올을 사용한다. The organic solvent may be an organic solvent commonly used in the art, and examples thereof include alcohols such as phenoxyethanol, propiparaben, oxyphenol, benzophenone, and ethanol, and preferably ethanol. do.
추출물은 7배 내지 13배, 바람직하게는 8배 내지 12배 감압 농축하여 시료를 제조한 후 -50℃이하, 바람직하게는 -60℃ 내지 -80℃인 초저온 냉장고에 보관한다. The extract is concentrated 7 times to 13 times, preferably 8 times to 12 times under reduced pressure to prepare a sample, and then stored in an ultra-cold refrigerator having a temperature of -50 ° C or less, preferably -60 ° C to -80 ° C.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples will be described in detail to help understand the present invention. However, the following examples are merely to illustrate the content of the present invention is not limited to the scope of the present invention. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
<< 실시예Example 1> 유자 추출물 제조 1> Citron Extract Manufacturer
도 1은 유자 추출물을 포함하는 시료의 제조 과정의 모식도이다. 1 is a schematic diagram of a process for preparing a sample containing citron extract.
고흥산 유자청 제조 후 냉동 상태의 부산물을 녹여 과피, 속씨, 씨앗껍질 별로 분류하였다. 분류된 부위별로 동결건조하여 건조 분말상태로 각 부위별로 -20℃에 보관하였다. 추출 시 각 분말 20g을 200ml 에탄올로 60℃ 열수 추출하였다. 추출물은 10배 감압 농축하여 시료를 제조한 후, -70℃ 초저온 냉동고에 보관하였다. After the production of Goheungsan Citron, the frozen by-products were dissolved and classified into skins, soybean seeds and seed shells. Freeze-drying for each classified site and stored at -20 ℃ for each site in dry powder form. At the time of extraction, 20 g of each powder was extracted with hot water at 60 ° C. with 200 ml ethanol. Extract was concentrated 10 times under reduced pressure to prepare a sample, and then stored in -70 ℃ ultra low temperature freezer.
실시예 2 내지 6은 세포 실험(in vitro)이므로 이에 추가적으로 상기 시료를 동결 건조 하여 건조된 분말을 얻은 후 이를 다이메틸설폭사이드에 녹여 실험하였다. 이때 다이메틸설폭사이드 100중량부 대비 건조분말 1 중량부를 사용하였다. Since Examples 2 to 6 are cell experiments (in vitro), the samples were further freeze-dried to obtain a dried powder, which was then dissolved in dimethyl sulfoxide. At this time, 1 part by weight of dry powder relative to 100 parts by weight of dimethyl sulfoxide was used.
<< 실시예Example 2> 세포독성 및 세포 성장 촉진 효과 평가 ( 2> Evaluation of cytotoxicity and cell growth promoting effect MTTMTT assayassay ))
피부각질세포(HaCaT Keratinocyte)를 페니실린 (100 IU/mL), 스트렙토마이신 (100 g/mL), 10% FBS (fetal bovine serum)를 함유하는 DMEM (Dulbecco's Modified Eagle's Medium) 배지에 넣고 37℃를 유지하며 5% 이산화탄소를 포함하는 배양기 내에서 배양하였다. 수득된 피부각질세포를 12-웰 플레이트에 각 웰당 1×105 개로 분주한 다음 같은 세포배양조건에서 24시간 배양하였다. 배양 후 세포에 유자 추출 물을 0.0025%, 0.005% 농도로 첨가한 후 24시간 배양하였다. 그 후 세포수를 측정하여 세포사멸 정도 및 세포 성장 촉진효과를 측정하였다. 결과를 도 2에 나타내었다. HaCaT Keratinocytes were placed in DMEM (Dulbecco's Modified Eagle's Medium) medium containing penicillin (100 IU / mL), streptomycin (100 g / mL) and 10% FBS (fetal bovine serum) and maintained at 37 ° C. And cultured in an incubator containing 5% carbon dioxide. The obtained keratinocytes were dispensed into 12-well plates at 1 × 10 5 per well and incubated for 24 hours under the same cell culture conditions. After incubation, the extract was added to the cells at a concentration of 0.0025% and 0.005%, and then cultured for 24 hours. After that, the number of cells was measured to measure the degree of cell death and cell growth promoting effect. The results are shown in FIG.
자외선을 처리한 실험군(도 2a)과 처리하지 않은 실험군(도 2b)으로 나누어 실험을 수행하였는데, 유자 추출물 0.0025%, 0.005% 농도에서 세포 독성은 없었으며, 자외선에 대한 세포 성장 촉진 효과를 보였다. The experiment was divided into UV treated experimental group (Fig. 2a) and untreated experimental group (Fig. 2b). There was no cytotoxicity at concentrations of 0.0025% and 0.005% of citron extract and showed cell growth promoting effect on UV.
<< 실시예Example 3> 자외선에 의해 유발되는 염증반응 억제실험 3> Inhibition of inflammatory reactions caused by ultraviolet rays
일반적으로 피부세포, 특히 표피세포인 각질형성세포(keratinocyte)가 자외선에 의해 조사되면 활성산소종이 형성되며 TNF-a, IL-1a 등 염증성 사이토카인의 증가와 함께 ERK, JNK 등의 작용으로 AP-1 전사인자가 활성화되면서 일련의 피부노화과정이 진행되는 것으로 알려져 있다. 배양중인 각질형성세포(keratinocyte)에 자외선을 조사하고 동시에 유자 추출물을 처리하였을 때 이들 염증성 사이토카인을 감소시키는 것을 탐색하였다.In general, when skin cells, especially keratinocytes, which are epidermal cells, are irradiated with ultraviolet light, reactive oxygen species are formed. In addition, the inflammatory cytokines such as TNF-a and IL-1a are increased, and the action of AP- It is known that a series of skin aging processes proceed as transcription factors are activated. The keratinocytes in culture were irradiated with UV light and simultaneously treated with citron extracts to reduce these inflammatory cytokines.
피부각질세포(HaCaT Keratinocyte)를 페니실린 (100 IU/mL), 스트렙토마이신 (100 g/mL), 10% FBS (fetal bovine serum)를 함유하는 DMEM (Dulbecco's Modified Eagle's Medium) 배지에 넣고 37℃를 유지하며 5% 이산화탄소를 포함하는 배양기 내에서 배양하였다. 수득된 피부각질세포를 12-웰 플레이트에 각 웰당 1× 105 개로 분주한 다음 같은 세포배양조건에서 24시간 배양하였다. 배양 후 세포에 12.5mJ/Cm2 량의 자외선을 조사한 후 유자 추출물을 0.0025%, 0.005% 농도로 첨가한 후 24시간 추가 배양하였다. 배양 후 배양 상등액을 회수하여 염증성 사이토카인인 TNF-α의 분비량을 측정하였다. 측정 결과를 도 3에 나타내었다. HaCaT Keratinocytes were placed in DMEM (Dulbecco's Modified Eagle's Medium) medium containing penicillin (100 IU / mL), streptomycin (100 g / mL) and 10% FBS (fetal bovine serum) and maintained at 37 ° C. And cultured in an incubator containing 5% carbon dioxide. The obtained keratinocytes were dispensed into 12-well plates at 1 × 10 5 per well and incubated for 24 hours under the same cell culture conditions. After culturing, the cells were irradiated with 12.5mJ / Cm 2 of ultraviolet rays, and then citron extract was added at a concentration of 0.0025% and 0.005%, and further cultured for 24 hours. After culturing, the culture supernatant was recovered and the amount of inflammatory cytokine TNF-α was measured. The measurement results are shown in FIG. 3.
도 3을 보면, 유자 추출물 0.0025, 0.005% 농도에서 자외선에 의해 분비가 증가되는 염증 유발 사이토카인(pro-inflammatory cytokine)인 TNF-α의 분비가 감소됨을 알 수 있다. 3, the secretion of TNF-α, an inflammation-induced cytokine (pro-inflammatory cytokine) in which the secretion of citron extracts is increased by ultraviolet rays at 0.0025, 0.005% concentration, is reduced.
<< 실시예Example 4> 콜라겐 분해 효소 측정 항노화 실험 4> Collagen Degrading Enzyme Determination Anti-aging Experiment
사람 섬유아세포(normal human fibroblast)를 페니실린 (100 IU/mL), 스트렙토마이신 (100 g/mL), 10% FBS (fetal bovine serum)를 함유하는 DMEM (Dulbecco's Modified Eagle's Medium) 배지에 넣고 37℃를 유지하며 5% 이산화탄소를 포함하는 배양기 내에서 배양하였다. 수득된 섬유아세포를 6-웰 플레이트에 각 웰당 1× 105 개로 분주한 다음 같은 세포배양조건에서 24시간 배양하였다. 배양 후 FBS를 함유하지 않은 배지에서 24시간 배양하고 세포에 15mJ/Cm2량의 자외선을 조사한 후 유자 추출물을 각각의 농도로 첨가한 후 72시간 추가 배양하였다. 배양 후 배양 상등액을 회수하여 콜라겐 분해효소 (MMP) 분비량을 웨스턴 블랏 (Western blot)으로 측정하였다. 그 결과를 도 4에 나타내었다.Normal human fibroblasts are placed in DMEM (Dulbecco's Modified Eagle's Medium) medium containing penicillin (100 IU / mL), streptomycin (100 g / mL) and 10% FBS (fetal bovine serum). The culture was maintained in an incubator containing 5% carbon dioxide. The obtained fibroblasts were dispensed into 6-well plates at 1 × 10 5 per well and incubated for 24 hours under the same cell culture conditions. After incubation for 24 hours in a medium not containing FBS, and irradiated with 15mJ / Cm 2 of ultraviolet rays to the cells after the addition of the citron extract at each concentration was further cultured for 72 hours. After the culture, the culture supernatant was collected and the amount of collagen degrading enzyme (MMP) was measured by Western blot. The results are shown in FIG.
도 4를 보면, 유자 추출물 0.0025, 0.005% 농도에서 자외선에 의해 분비가 증가되는 콜라겐 분해 효소(MMPs)의 분비가 감소함을 알 수 있다.Referring to Figure 4, it can be seen that the secretion of collagen degrading enzymes (MMPs), which are increased by the ultraviolet rays at concentrations of 0.0025 and 0.005% of the citron extract is reduced.
<< 실시예Example 5> 멜라닌 분비량 측정을 통한 미백효과 검토 5> Review of whitening effect by measuring melanin secretion
마우스 유래 악성 멜라닌 종양 세포주 B16F1 (KCLB 8007)를 페니실린 (100 IU/mL), 스트렙토마이신 (100 g/mL), 10% FBS (fetal bovine serum)를 함유하는 DMEM (Dulbecco's Modified Eagle's Medium) 배지에 넣고 37℃를 유지하며 5% 이산화탄소를 포함하는 배양기 내에서 배양하였다. 수득된 멜라닌 종양 세포를 24웰 플레이트(well plate)에 1×104 세포/웰(cells/well)에 접종(seeding)하여 1일 배양하였다. 배양 후 배지를 제거한 다음, 멜라닌 합성을 유도시키기 위하여, alpha-MSH (melanocyte stimulating hormone; 멜라노사이트 자극 호르몬)을 비처리군을 제외하고 5 nM을 첨가하여 멜라닌 합성을 유도하였고, 동시에 유자 추출물 및 코직산 (양성대조군) 800 μM를 가한 DMEM 배지를 첨가하여 3일간 배양하였다. 각 처리군의 세포를 수거하여 10% DMSO (Dimethyl sulfoxide)와 1N NaOH 100 ㎕를 각각 첨가하여 멜라닌을 용해하였고, 405nm에서의 흡광도를 측정하여 멜라닌 량을 측정하였다. 결과를 도 5에 나타내었다. Mouse-derived malignant melanin tumor cell line B16F1 (KCLB 8007) was placed in DMEM (Dulbecco's Modified Eagle's Medium) medium containing penicillin (100 IU / mL), streptomycin (100 g / mL) and 10% FBS (fetal bovine serum) Culture was maintained in an incubator containing 5% carbon dioxide while maintaining 37 ℃. The obtained melanin tumor cells were seeded in 1 × 10 4 cells / well in a 24-well plate and cultured for 1 day. After incubation, the medium was removed, and in order to induce melanin synthesis, melanin synthesis was induced by adding 5 nM of alpha-MSH (melanocyte stimulating hormone) except for the untreated group. (Positive control) DMEM medium to which 800 μM was added was added and cultured for 3 days. Cells of each treatment group were harvested, 10% DMSO (dimethyl sulfoxide) and 100 μl of 1N NaOH were added to dissolve melanin, and the melanin content was measured by measuring absorbance at 405 nm. The results are shown in FIG.
도 5를 보면, 유자 추출물 0.01 0.02% 농도에서 α-MSH에 의한 세포 내 분비된 멜라닌(Secreted melanin)의 양이 과피와 껍질에서 감소함을 알 수 있다. 특히 0.02% 농도에서는 표준물질인 코직산(Kojic acid)와 비슷한 활성을 나타내었다.Referring to Figure 5, it can be seen that the amount of secreted melanin secreted by the α-MSH at the concentration of 0.02% citron extract decreased in the skin and skin. In particular, at 0.02% concentration, it showed similar activity to Kojic acid as a standard.
<< 실시예Example 6> 6> 타이로시나아제Tyrosinase 저해 활성 측정 효과 Inhibitory activity measurement effect
마우스 유래 악성 멜라닌 종양 세포주 B16F1 (KCLB 8007)를 페니실린 (100 IU/mL), 스트렙토마이신 (100 g/mL), 10% FBS (fetal bovine serum)를 함유하는 DMEM (Dulbecco's Modified Eagle's Medium) 배지에 넣고 37℃를 유지하며 5% 이산화탄소를 포함하는 배양기 내에서 배양하였다. 수득된 멜라닌 종양 세포를 24웰 플레이트(well plate)에 1×104 세포/웰(cells/well)에 접종(seeding)하여 1일 배양하였다. 배양 후 배지를 제거한 다음, 멜라닌 합성을 유도시키기 위하여, alpha-MSH (melanocyte stimulating hormone; 멜라노사이트 자극 호르몬)을 비처리군을 제외하고 5 nM을 첨가하여 멜라닌 합성을 유도하였고, 동시에 유자 추출물 및 코직산 (양성대조군) 800 μM를 가한 DMEM 배지를 첨가하여 48시간 동안의 배양 후 RIPA buffer 를 이용하여 cell을 lysis 하였다. 브래드포드 분석(Bradford assay)을 통해 β-mercaptoethanol 을 첨가하지 않은 래밀리 샘플 완충용액(laemmli sample buffer)을 이용해 단백질량을 모두 동일하게 보정하였다. 단백질을 가열하는 과정을 생략하고8% SDS-PAGE (Sodium Dodecyl Sulfate Poly Acrylamide Gel Electrophoresis)를 한 후에 gel을 0.1M SPB (Sodium phosphate buffer, pH 6.8)로 30분 동안 shaking 하면서 equilibration 하였다. 한 번의 equilibration 을 추가로 반복한 후에 staining 은 5mM L-DOPA 를 SPB에 녹여 37℃ 에서 약 1시간 동안 발색이 나타날 때까지 반응시켰다. 결과를 도 6에 나타내었다. Mouse-derived malignant melanin tumor cell line B16F1 (KCLB 8007) was placed in DMEM (Dulbecco's Modified Eagle's Medium) medium containing penicillin (100 IU / mL), streptomycin (100 g / mL) and 10% FBS (fetal bovine serum) Culture was maintained in an incubator containing 5% carbon dioxide while maintaining 37 ℃. The obtained melanin tumor cells were seeded in 1 × 10 4 cells / well in a 24-well plate and cultured for 1 day. After incubation, the medium was removed, and in order to induce melanin synthesis, melanin synthesis was induced by adding 5 nM of alpha-MSH (melanocyte stimulating hormone) except for the non-treated group, and at the same time, citron extract and kojic acid (Positive control group) 800 μM was added to the DMEM medium and cultured for 48 hours, and then cells were lysed using RIPA buffer. The amount of protein was equally corrected by using a Laemmli sample buffer to which β-mercaptoethanol was not added through the Bradford assay. After heating the protein and skipping 8% SDS-PAGE (Sodium Dodecyl Sulfate Poly Acrylamide Gel Electrophoresis), the gel was equilibrated while shaking with 0.1M SPB (Sodium phosphate buffer, pH 6.8) for 30 minutes. After one additional round of equilibration, staining was dissolved in 5 mM L-DOPA in SPB and allowed to react at 37 ° C for about 1 hour until color development appeared. The results are shown in FIG.
도 6을 보면 유자 추출물 0.01 0.02% 농도에서 α-MSH에 의한 멜라닌 생성에 관여하는 타이로시나제 양이 과피와 껍질에서 감소함을 알 수 있다. 특히 0.02% 농 도에서는 표준물질인 코직산(Kojic acid) 보다 좋은 활성을 나타내었다.Referring to Figure 6 it can be seen that the amount of tyrosinase involved in melanogenesis by α-MSH at the concentration of 0.02% citron extract is reduced in the skin and peel. In particular, at 0.02% concentration, it showed better activity than the standard kojic acid.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시예일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다. Having described the specific parts of the present invention in detail, it will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments, and thus the scope of the present invention is not limited thereto. will be. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
도 1은 유자 추출물을 포함하는 시료의 제조 과정의 모식도이다. 1 is a schematic diagram of a process for preparing a sample containing citron extract.
도 2는 세포독성 및 세포 성장 촉진 효과 평가 (MTT assay)이며, a는 자외선을 처리한 군, b는 자외선을 처리하지 않은 군이다. 2 is a cytotoxicity and cell growth promoting effect evaluation (MTT assay), a is a group treated with ultraviolet rays, b is a group not treated with ultraviolet rays.
도 3은 자외선에 의해 유발되는 염증반응 억제시험의 결과 그래프이다.Figure 3 is a graph of the results of the inflammatory response inhibition test induced by ultraviolet light.
도 4는 콜라겐 분해 효소 분비량을 측정한 결과이다. 4 is a result of measuring the amount of collagenase enzyme secretion.
도 5는 Secreted Melanin Assay 결과 그래프이다. 5 is a graph of Secreted Melanin Assay results.
도 6은 타이로시나제 저해 활성 측정 결과이다. 6 shows the results of measuring tyrosinase inhibitory activity.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090104601A KR20110047824A (en) | 2009-10-30 | 2009-10-30 | Cosmetic composition containing citron extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090104601A KR20110047824A (en) | 2009-10-30 | 2009-10-30 | Cosmetic composition containing citron extract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20110047824A true KR20110047824A (en) | 2011-05-09 |
Family
ID=44239055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090104601A Withdrawn KR20110047824A (en) | 2009-10-30 | 2009-10-30 | Cosmetic composition containing citron extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20110047824A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101383145B1 (en) * | 2012-08-08 | 2014-04-10 | 한국인스팜(주) | A composition comprising the extract of Citrus junos for preventing and treating benign prostatic hyperplasia |
KR101425031B1 (en) * | 2013-08-13 | 2014-08-01 | 엄익현 | Cosmetic composition for anti-irritation and skin moisturization containing Citrus junos Siebold seed oil and Mangifera Indica seed oil |
WO2017043670A1 (en) * | 2015-09-07 | 2017-03-16 | 엄익현 | Cosmetic composition containing citron extract |
WO2018236007A1 (en) * | 2017-06-21 | 2018-12-27 | 주식회사 마린테크노 | Whitening cosmetic composition containing citrus junos seed extract as active ingredient |
KR102411718B1 (en) * | 2022-04-12 | 2022-06-22 | 주식회사 서울화장품 | Preparation method of citrus junos seed extract and cosmetic composition containing the same |
KR20220090744A (en) | 2020-12-23 | 2022-06-30 | 전라남도 | A cosmetic composition for aromatherapy comprising of Yuza citron extract and aroma complex hydrosol and preparation method thereof |
KR20220132835A (en) * | 2021-03-24 | 2022-10-04 | (주)헤세드바이오 | Mixed extract for skin enhancement and a cosmetic composition comprising the same |
KR102785965B1 (en) * | 2024-11-26 | 2025-03-26 | (주)엔비바이오컴퍼니 | A Cosmetic composition for skin whitening comprising Rice bran extract, Fig extract, Nymphaea Alba flower extract and Yuja extract |
-
2009
- 2009-10-30 KR KR1020090104601A patent/KR20110047824A/en not_active Withdrawn
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101383145B1 (en) * | 2012-08-08 | 2014-04-10 | 한국인스팜(주) | A composition comprising the extract of Citrus junos for preventing and treating benign prostatic hyperplasia |
KR101425031B1 (en) * | 2013-08-13 | 2014-08-01 | 엄익현 | Cosmetic composition for anti-irritation and skin moisturization containing Citrus junos Siebold seed oil and Mangifera Indica seed oil |
WO2017043670A1 (en) * | 2015-09-07 | 2017-03-16 | 엄익현 | Cosmetic composition containing citron extract |
WO2018236007A1 (en) * | 2017-06-21 | 2018-12-27 | 주식회사 마린테크노 | Whitening cosmetic composition containing citrus junos seed extract as active ingredient |
KR20220090744A (en) | 2020-12-23 | 2022-06-30 | 전라남도 | A cosmetic composition for aromatherapy comprising of Yuza citron extract and aroma complex hydrosol and preparation method thereof |
KR20220132835A (en) * | 2021-03-24 | 2022-10-04 | (주)헤세드바이오 | Mixed extract for skin enhancement and a cosmetic composition comprising the same |
KR102411718B1 (en) * | 2022-04-12 | 2022-06-22 | 주식회사 서울화장품 | Preparation method of citrus junos seed extract and cosmetic composition containing the same |
KR102785965B1 (en) * | 2024-11-26 | 2025-03-26 | (주)엔비바이오컴퍼니 | A Cosmetic composition for skin whitening comprising Rice bran extract, Fig extract, Nymphaea Alba flower extract and Yuja extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102331436B1 (en) | Composition Comprising Glycoprotein Fraction of the Flower Extract or Hydrolysate Derived from the Glycoprotein Fraction, and Method of Producing Glycoprotein Fraction of the Flower Extract and Hydrolysate Derived from the Glycoprotein Fraction | |
KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
KR20110047824A (en) | Cosmetic composition containing citron extract | |
JP7708495B2 (en) | Anti-aging agents, antioxidants, anti-inflammatory agents, skin whitening agents, and cosmetics | |
KR102050545B1 (en) | An anti-aging functional cosmetic composition comprising an Undaria pinnatifida extract, an Ecklonia cava extract and glycosaminoglycan | |
KR102154927B1 (en) | A cosmetic composition for anti-aging, anti-oxidant, skin regeneration comprising chlorogenic acid, ferulic acid, resveratrol, and Streptococcus thermophilus fermented extract | |
KR20160009752A (en) | Composition comprising Dendrobium moniliforme Extract for skin whitening and anti-wrinkle Effects, Functional food and Korean herb cosmetic manufactured by using them | |
JP6437342B2 (en) | A skin external preparation or an internal preparation containing an extract of echinacea cultivated by irradiating light having a specific wavelength range. | |
KR100860605B1 (en) | Cosmetic Composition Containing Strobe Pine Bark Extract and Niacinamide | |
KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
KR20130115455A (en) | Whitening and anti-wrinkle composition | |
KR102011654B1 (en) | Cosmetic composition comprising oysters, sea cucumber, sea squirt, Aplysia kurodai and buccinum striatissimum | |
KR101207559B1 (en) | Cosmetic composition comprising the extract of Pourthiaea villosa as active ingredient | |
KR101802341B1 (en) | Cosmetic composition comprising extract of plant belonging to the genus nynphoides for improving skin | |
KR20140089305A (en) | Composition for improving skin whitening or skin wrinkle comprising extracts of Quercus salicina Blume | |
KR102168533B1 (en) | Cosmetic composition for whitening or improving the facial color containing herb extracts | |
KR102289135B1 (en) | Herbal medicine mixed extract and uses therof | |
KR100542446B1 (en) | Cosmetic composition whose extract is the main active ingredient | |
KR20120036516A (en) | Cosmetic compositions for skin whitening comprising broccoli seed extracts | |
KR20210038024A (en) | A composition for skin whitening comprising Cinnamomum camphora extract | |
KR101531484B1 (en) | Cosmetic composition for whitening skin comprising extract of Diospyros lotus leaf as effective component | |
KR102785965B1 (en) | A Cosmetic composition for skin whitening comprising Rice bran extract, Fig extract, Nymphaea Alba flower extract and Yuja extract | |
KR20160013435A (en) | Cosmetic composition comprising Juncus effusus extract for improving elasticity of skin and wrinkle | |
KR102784518B1 (en) | A composition for skin whitening or anti-wrinkle comprising Alopecurus aequalis extracts | |
KR102746298B1 (en) | A cosmetic composition comprising rucinol and natural extracts for skin-whitening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20091030 |
|
PG1501 | Laying open of application | ||
PC1203 | Withdrawal of no request for examination | ||
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |